Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses

Vaccine

Volumn 28, Issue 5, 2010, Pages 1383-1390

  Dominguez, Ana Lucia ^a   Lustgarten, Joseph ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

CD40; Dendritic cells and immunotherapy; Nanoparticles; RNEU; T cell responses

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 MONOCLONAL ANTIBODY; NANOPARTICLE; NEU MONOCLONAL ANTIBODY; POLYLACTIC ACID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; IMMUNOLOGIC MEMORY; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYMERS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 74149087438     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.153     Document Type: Article

References (52)

1. Lurquin C., Pel A.V., Mariame B., Plaen E.D., Szikora J., Janssens C., et al. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58 (1989) 293
2. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
3. El-Shami K., Tirosh B., Popovic D., Carmon L., Tzehoval E., Vadai E., et al. Induction of antitumor immunity by proteasome-inhibited sygeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer 85 (2000) 236
4. Valmori D., Levy F., Miconnent I., Zajac P., Spagnoli G., Rimoldi D., et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164 (2000) 1125
5. Romero P., Cerottini J.C., and Speiser D. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 53 3 (2004) 249-255
6. Steinman R., and Banchereau J. Taking dendritic cells into medicine. Nature 449 7161 (2007) 419-426
7. Lustgarten J., Dominguez A., and Cuadros C. The CD8+ T cell reperoire against RNEU antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol 34 (2004) 752
8. Nouri-Shirazi M., Banchereau J., Bell D., Burkeholder S., Kraus E., Davoust J., et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 165 7 (2000) 3797-3803
9. Driessens G., Gordower L., Nuttin L., Stordeur P., Blocklet D., Egrise D., et al. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration. Cancer Immunol Immunother 57 12 (2008) 1745-1756
10. Teramoto K., Kontani K., Fujita T., Ozaki Y., Sawai S., Tezuka N., et al. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA. Cancer Immunol Immunother 56 3 (2007) 331-342
11. Avigan D., Vasir B., George D., Oh W., Atkins M., McDermott D., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30 7 (2007) 749-761
12. Palmer D., Midgley R., Mirza N., Torr E., Ahmed F., Steele J., et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49 1 (2009) 124-132
13. Cuadros C., Dominguez A., Lollini P., Croft M., Mittler R., Borgstrom P., et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in RNEU transgenic mice. Int J Cancer 116 (2005) 934-943
14. Grewal I., Borrow P., Pamer E., Oldstone M., and Flavell R. The CD40-CD154 system in anti-infective host defense. Curr Opin Immunol 9 (1997) 491
15. Grewal I., and Flavell R. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153 (1996) 85
16. Tanchot C., and Rocha B. CD8 and B cell memory: same strategy, same signals. Nat Immunol 4 (2003) 431
17. Bennett S., Carbone F., Karamalis F., Flavell R., Miller J., and Heath W. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393 (1998) 474
18. Ridge J., Di Rosa F., and Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 474 (1998) 474
19. Schoenberger S., Toes R., van der Voort E., Offringa R., and Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480
20. Bourgeois C., Rocha B., and Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297 (2002) 2060
21. van Mierlo G., Boonman Z., Dumortier H., den Boer A., Fransen M., Nouta J., et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 173 (2004) 6753
22. Watanabe S., Kagamu H., Yoshizawa H., Fujita N., Tanaka H., Tanaka J., et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol 171 (2003) 5828
23. Kedl R., Jordan M., Potter T., Kappler J., Marrack P., and Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 98 (2001) 10811
24. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6 (2006) 688-701
25. Kawasaki E., and Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1 (2005) 101-109
26. Vo-Dinh T., Kasili P., and Wabuyele M. Nanoprobes and nanobiosensors for monitoring and imaging individual living cells. Nanomedicine 2 (2006) 22-30
27. Artemov D., Mori N., Okollie B., and Bhujwalla Z. MR molecular imaging of the RNEU receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 49 (2003) 403-408
28. Mitra A., Nan A., Line B., and Ghandehari H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12 (2006) 4729-4749
29. Will O., Purkayastha S., Chan C., Athanasiou T., Darzi A., Gedroyc W., et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7 (2006) 52-60
30. Rovero S., Amici A., Carlo E., Bei P., Nanni P., Quaglino E., et al. DNA vaccination against rat RNEU p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic Balb/c mice. J Immunol 165 (2000) 5133-5142
31. Sharma S., Dominguez A., Hoelzinger D., and Lustgarten J. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother 57 (2008) 549-561
32. Llopiz D., Doctor J., Zabaleta A., Lasarte J., Prieto J., Borras-Cuesta F., et al. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 57 1 (2008) 19-29
33. Murphy W., Welniak L., Back T., Hixon J., Subleski J., Seki9 N., et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 170 (2003) 2727
34. Assudani D., Cho H., DeVito N., Bradley N., and Celis E. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68 23 (2008) 9892-9899
35. Ito D., Ogasawara K., Iwabuchi K., Inuyama Y., and Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol 164 3 (2000) 1230-1235
36. Anderson B., Kudelka A., Honda T., Pollack M., Gershenson D., Gillogly M., et al. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49 9 (2000) 459-468
37. Lopez M., Adris S., Bravo A., Chernajovsky Y., and Podhajcer D. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J Immunol 175 9 (2005) 5885-5894
38. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
39. Dominitzki S., Fantini M., Neufert C., Nikolaev A., Galle P., Scheller J., et al. Cutting edge: trans-signaling via the soluble Il-6R abrogates the induction of FoxP3 in naive CD4+CD25+ T cells. J Immunol 179 (2007) 2041-2045
40. Sakaguchi S., Yamaguchi T., Nomura T., and Ono M. Regulatory T cells and immune tolerance. Cell 133 (2008) 775-787
41. Sharma S., Dominguez A., Manrique S., Cavallo F., Sakaguchi S., and Lustgarten J. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 68 (2008) 7530-7540
42. Tanaka H., Tanaka J., Kjaergaard J., and Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25 3 (2002) 207-217
43. Ge W., Li Y., Li Z., Zhang S., Sun Y., Hu P., et al. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol Immunother 58 2 (2009) 201-208
44. Wang X., Uto T., Akagi T., Akashi M., and Baba M. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 81 18 (2007) 10009-10016
45. de Jong S., Chikh G., Sekirov L., Raney S., Semple S., Klimuk S., et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneiously administered CpG ODN. Cancer Immunol Immunother 56 8 (2007) 1251-1264
46. Sabel M., Arora A., Su G., Griffith K., Mathiowitz E., Reineke J., et al. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres. J Immunother 30 8 (2007) 808-816
47. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26 (2008) 5046-5057
48. Rege K., Patel S., Megeed Z., and Yarmush M. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 67 (2007) 6368-6375
49. Davis M., Chen Z., and Shin D. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7 (2008) 771-782
50. Chames P., and Baty D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12 (2009) 276-283
51. Cuadros C., Dominguez A., Frost G., Borgstrom P., and Lustgarten J. Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection intolerant RNEU mice. Cancer Res 63 (2003) 5895-5901
52. Singh M., Chkrapani A., and O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 6 5 (2007) 797-808